Gemini said

Medication Name: Mounjaro® Slug: Mounjaro Hero Title: Mounjaro®: A Dual-Action Canadian Injectable Hero Description: This guide provides pharmaceutical information for educational purposes. Please consult a doctor for personalized medical advice regarding any health treatments.

Table of Contents

• Generic Name
• Other Brand Names
• Drug Class
• Detailed Overview
• Mechanism of Action
• Dosage Forms
• Dosage Instructions
• Side Effects
• Important Safety Information
• Interactions
• Storage Instructions
• Prescription Status
• Canadian DIN
• Summary Points
• Frequently Asked Questions
• Category
• Alternatives

Image Description: A clean, professional 3D render of a Mounjaro® KwikPen® sitting on a white surface, showing the dosage window and grey cap.

Generic Name: Tirzepatide

Other Brand Names: Zepbound™

Drug Class: Dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist.

Detailed Overview

Mounjaro® contains tirzepatide and is used to manage metabolic processes through a unique dual-hormone signaling pathway.

Mounjaro® is a brand-name pharmaceutical product developed by Eli Lilly. It is a long-acting injectable medication that specifically targets two different pathways in the body. Unlike older medications that only mimic one hormone, Mounjaro® is the first in a new class that activates two distinct receptors simultaneously.

Mechanism of Action

This medication activates two natural hormone receptors in the body to help regulate blood sugar and energy levels.

The active ingredient, tirzepatide, works by mimicking the action of two "incretin" hormones:

1. GIP: Helps improve the body's response to energy intake.
2. GLP-1: Influences how the body processes sugar and manages satiety.

By binding to both of these receptors, the medication helps the pancreas release the appropriate amount of insulin after eating and slows down the speed at which food leaves the stomach.

Dosage Forms

Mounjaro® is available in Canada as single-dose vials and multi-dose pens in various strengths.

In the Canadian market, this medication is typically supplied in the following formats:

• Mounjaro® KwikPen®: A pre-filled pen containing 4 weekly doses.
• Single-Dose Vials: Individual vials for a single injection.
• Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose (usually in 0.5 mL or 0.6 mL).

Dosage Instructions

It is typically administered as a weekly subcutaneous injection, with doses gradually adjusted by a healthcare professional.

• Frequency: Once every seven days.
• Method: Injected under the skin (subcutaneously) in the abdomen, thigh, or back of the upper arm.
• Adjustment: Doctors usually start patients on a low dose (e.g., 2.5 mg) and increase it slowly over several months to improve tolerability.
• Safety: The injection site should be rotated each week.

Side Effects

Digestive issues are the most frequent reaction; however, serious risks should be discussed with a medical doctor.

Common Side Effects

Serious Physiological Reactions

Nausea and vomiting

Severe abdominal pain (Pancreatitis risk)

Diarrhea or constipation

Changes in vision

Decreased appetite

Severe allergic reactions (Rash, swelling)

Indigestion (dyspepsia)

Kidney issues (due to dehydration)

Certain health conditions and family history must be shared with a physician before starting this prescription medication.

• Thyroid Warning: Mounjaro® has a warning regarding the risk of thyroid C-cell tumors based on animal studies. It should not be used by individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC).
• Pancreas Health: Patients with a history of pancreatitis should use this medication with caution.
• Pregnancy/Nursing: Consult a doctor, as the effects on human pregnancy are not fully established.

Since it affects digestion speed, this medication can change how the body absorbs other oral pills or supplements.

• Oral Medications: Because Mounjaro® slows stomach emptying, it may delay the absorption of other medications taken by mouth.
• Birth Control: Women using oral contraceptives may need to switch to a non-oral method for a period when starting or increasing doses.
• Insulin/Sulfonylureas: Using Mounjaro® alongside other sugar-regulating medications can increase the risk of low blood sugar.